Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Exploratory Study to Evaluate the Efficacy and Safety of HAD-B1 for Dose-Finding in EGFR Mutation Positive and Locally Advanced or Metastatic NSCLC Subjects Who Need Afatinib Therapy

Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Exploratory Study to Evaluate the Efficacy and Safety of HAD-B1 for Dose-Finding in EGFR Mutation Positive and Locally Advanced or Metastatic NSCLC Subjects Who Need Afatinib Therapy

Afatinib is a target anticancer drug of the second-generation EGFR TKI type, showing an advantage in treatment effect compared to conventional chemotherapy. However, patients on EGFR-TKI drugs also usually progress after 9 to 13 months according to secondary resistance. HAD-B1 is composed of drugs t...

Full description

Bibliographic Details
Main Authors: Eun-Ju Ko KMD, MS, Eun-Bin Kwag MS, Ji Hye Park KMD, PhD, So-Jung Park KMD, PhD, Ji-Woong Son MD, PhD, Seong-Hun Yoon MD, PhD, Seong-Hun Shin MD, PhD, Hwa-Seung Yoo KMD, PhD
Format: Article
Language:English
Published: SAGE Publishing 2021-08-01
Series:Integrative Cancer Therapies
Online Access:https://doi.org/10.1177/15347354211037917

Similar Items

Similar Items